Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 69

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 69
---
 product candidate or may elect not to                                                                                                                                         
 continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business 
 combination that diverts resources or creates competing priorities;                                                                                                                                                                                 |

| • |     | collaborators could independently develop, or develop with third parties, products that compete directly or 
 indirectly with our product candidate;                                                                      |

| • |     | a collaborator with marketing, manufacturing, and distribution rights to one or more products may not commit 
 sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;            |

| • |     | we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; |

| • |     | collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual                                                                                                                
 property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; |

| • |     | disputes may arise between us and a collaborator that causes the delay or termination of the research,                                                                 
 development or commercialization of our future product candidates or that results in costly litigation or arbitration that diverts management attention and resources; |

| • |     | collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue 
 further development or commercialization of the applicable future product candidates;                       |

| • |     | collaborators may own or co-own intellectual property covering our                                                                                                                    
 product candidate that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and |

| • |     | a collaborator’s sales and marketing activities or other operations may not be in compliance with 
 applicable laws resulting in civil or criminal proceedings.                                       |

In addition, any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses, or acquired in-processresearch and development expenses, any of which could affect our financial condition, liquidity, and results of operations. 44

Future acquisitions may also require us to obtain additional financing, which may not be
available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of our management. In